NasdaqCM - Delayed Quote USD

Quoin Pharmaceuticals, Ltd. (QNRX)

Compare
0.7519 -0.1127 (-13.03%)
At close: October 22 at 4:00 PM EDT
0.8400 +0.09 (+11.72%)
Pre-Market: 6:43 AM EDT
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
8,938.2920
9,378.5040
9,257.7040
6,062.8500
1,670.0100
Operating Income
-8,938.2920
-9,378.5040
-9,257.7040
-6,062.8500
-1,670.0100
Net Non Operating Interest Income Expense
657.7460
694.6140
-618.3360
-1,365.4090
-47.0210
Other Income Expense
2.6760
-2.6830
494.5440
-14,034.3290
-378.3330
Pretax Income
-8,277.8700
-8,686.5730
-9,381.4960
-21,462.5880
-2,095.3640
Net Income Common Stockholders
-8,277.8700
-8,686.5730
-9,446.7620
-21,462.5880
-2,095.3640
Diluted NI Available to Com Stockholders
-8,277.8700
-8,686.5730
-9,446.7620
-21,462.5880
-2,095.3640
Basic EPS
-5.05
-9.64
-46.81
-815.52
-37.66
Diluted EPS
-5.05
-9.64
-46.81
-815.52
-37.66
Basic Average Shares
2,282.5780
900.9190
201.8260
26.3160
55.6410
Diluted Average Shares
2,282.5780
900.9190
201.8260
26.3160
55.6410
Total Expenses
8,938.2920
9,378.5040
9,257.7040
6,062.8500
1,670.0100
Net Income from Continuing & Discontinued Operation
-8,277.8700
-8,686.5730
-9,381.4960
-21,462.5880
-2,095.3640
Normalized Income
-8,280.5460
-8,683.8900
-9,798.8030
-21,462.5880
-2,095.3640
Interest Income
657.7460
694.6140
95.7450
--
--
Interest Expense
--
--
714.0810
1,090.4090
47.0210
Net Interest Income
657.7460
694.6140
-618.3360
-1,365.4090
-47.0210
EBIT
-8,246.3610
-8,686.5730
-8,667.4150
-20,372.1790
-2,048.3430
EBITDA
-8,144.6770
-8,582.8670
-8,563.3720
-20,268.1360
-1,944.3000
Reconciled Depreciation
101.6840
103.7060
104.0430
104.0430
104.0430
Net Income from Continuing Operation Net Minority Interest
-8,277.8700
-8,686.5730
-9,381.4960
-21,462.5880
-2,095.3640
Total Unusual Items Excluding Goodwill
2.6760
-2.6830
417.3070
--
-378.3330
Total Unusual Items
2.6760
-2.6830
417.3070
--
-378.3330
Normalized EBITDA
-8,147.3530
-8,580.1840
-8,980.6790
-20,268.1360
-1,944.3000
12/31/2020 - 8/1/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers